🚀 VC round data is live in beta, check it out!
Merck KGaA Valuation Multiples
Discover revenue and EBITDA valuation multiples for Merck KGaA and similar public comparables like UCB, Takeda Pharmaceuticals, Jiangsu Hengrui Pharma, argenx and more.
Merck KGaA Overview
About Merck KGaA
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Founded
N/A
HQ
Employees
62.6K
Website
Financials (LTM)
EV
$70B
Merck KGaA Financials
Merck KGaA reported last 12-month revenue of $25B and EBITDA of $7B.
In the same LTM period, Merck KGaA generated $14B in gross profit, $7B in EBITDA, and $4B in net income.
Revenue (LTM)
Merck KGaA P&L
In the most recent fiscal year, Merck KGaA reported revenue of $25B and EBITDA of $7B.
Merck KGaA expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25B | XXX | $25B | XXX | XXX | XXX |
| Gross Profit | $14B | XXX | $15B | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $7B | XXX | $7B | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | $4B | XXX | $4B | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $11B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Merck KGaA Stock Performance
Merck KGaA has current market cap of $59B, and enterprise value of $70B.
Market Cap Evolution
Merck KGaA's stock price is $135.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70B | $59B | -1.9% | XXX | XXX | XXX | $9.66 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMerck KGaA Valuation Multiples
Merck KGaA trades at 2.8x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Merck KGaA Financial Valuation Multiples
As of April 18, 2026, Merck KGaA has market cap of $59B and EV of $70B.
Equity research analysts estimate Merck KGaA's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Merck KGaA has a P/E ratio of 14.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $59B | XXX | $59B | XXX | XXX | XXX |
| EV (current) | $70B | XXX | $70B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 9.8x | XXX | XXX | XXX |
| EV/EBIT | 15.1x | XXX | 15.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | 4.8x | XXX | XXX | XXX |
| P/E | 14.3x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | 25.5x | XXX | 29.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Merck KGaA Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Merck KGaA Margins & Growth Rates
Merck KGaA's revenue in the last 12 month grew by 2%.
Merck KGaA's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Merck KGaA's rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Merck KGaA's rule of X is 26% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Merck KGaA Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | (0%) | XXX | (4%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 41% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Merck KGaA Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Merck KGaA | XXX | XXX | XXX | XXX | XXX | XXX |
| UCB | XXX | XXX | XXX | XXX | XXX | XXX |
| Takeda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiangsu Hengrui Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| argenx | XXX | XXX | XXX | XXX | XXX | XXX |
| Zoetis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Merck KGaA M&A Activity
Merck KGaA acquired XXX companies to date.
Last acquisition by Merck KGaA was on XXXXXXXX, XXXXX. Merck KGaA acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Merck KGaA
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMerck KGaA Investment Activity
Merck KGaA invested in XXX companies to date.
Merck KGaA made its latest investment on XXXXXXXX, XXXXX. Merck KGaA invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Merck KGaA
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Merck KGaA
| Where is Merck KGaA headquartered? | Merck KGaA is headquartered in Germany. |
| How many employees does Merck KGaA have? | As of today, Merck KGaA has over 62K employees. |
| Is Merck KGaA publicly listed? | Yes, Merck KGaA is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Merck KGaA? | Merck KGaA trades under MRK ticker. |
| When did Merck KGaA go public? | Merck KGaA went public in 1995. |
| Who are competitors of Merck KGaA? | Merck KGaA main competitors are UCB, Takeda Pharmaceuticals, Jiangsu Hengrui Pharma, argenx. |
| What is the current market cap of Merck KGaA? | Merck KGaA's current market cap is $59B. |
| What is the current revenue of Merck KGaA? | Merck KGaA's last 12 months revenue is $25B. |
| What is the current revenue growth of Merck KGaA? | Merck KGaA revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Merck KGaA? | Current revenue multiple of Merck KGaA is 2.8x. |
| Is Merck KGaA profitable? | Yes, Merck KGaA is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Merck KGaA? | Merck KGaA's last 12 months EBITDA is $7B. |
| What is Merck KGaA's EBITDA margin? | Merck KGaA's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Merck KGaA? | Current EBITDA multiple of Merck KGaA is 10.0x. |
| What is the current FCF of Merck KGaA? | Merck KGaA's last 12 months FCF is $3B. |
| What is Merck KGaA's FCF margin? | Merck KGaA's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Merck KGaA? | Current FCF multiple of Merck KGaA is 25.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.